<DOC>
	<DOCNO>NCT00224484</DOCNO>
	<brief_summary>Main goal study compare occurrence serious adverse event ( SAEs ) herpes simplex ( gD2-AS04 ) vaccine group Saline control group throughout study period ( month 12 ) . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Safety Study Herpes Simplex Vaccine HSV Seronegative Seropositive Females Between 10 17 Years Old</brief_title>
	<detailed_description>Three group female ( 3000 , 1500 1500 subject , respectively ) inject 3 time ( month 0 , 1 6 ) herpes simplex vaccine , HavrixTM vaccine ( control ) Saline solution ( placebo ) , respectively . Subjects follow 18 month .</detailed_description>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol enrol study . Healthy female , include , 10 17 year age time first vaccination . Written inform assent obtain subject write informed consent obtain parent legal guardian subject prior enrolment . If subject legal age consent country , write informed consent obtain subject . Subjects must negative urine pregnancy test . Subjects childbearing potential time study entry must abstinent must use effective method birth control 30 day prior vaccination must agree continue precaution two month completion vaccination series . Subjects reach menarche study therefore childbearing potential must agree follow precaution . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Pregnant lactate female . Female plan become pregnant likely become pregnant first eight month study ( month 08 ) . Any previous confirmed history , current clinical sign symptom , oro labial herpes ( cold sore ) , herpetic whitlow genital herpes disease , swell , papule , vesicle , pustule , ulcer , crust , fissure , erythema , discharge , dysuria pain , burning , itch , tingle anogenital area . History previous plan vaccination hepatitis A history hepatitis A infection . Previous vaccination herpes . History herpetic keratitis . History multiform erythema . Planned administration/administration vaccine foreseen study protocol within 30 day 30 day first dose study vaccine follow exception : administration routine meningococcal , hepatitis B , inactivate influenza , diphtheria/tetanus and/or diphtheria/tetanuscontaining vaccine 8 day 30 day first dose study vaccine . History allergic disease reaction likely exacerbate component study vaccines Any confirm suspected immunosuppressive immunodeficient condition base medical history physical examination History current acute chronic autoimmune disease . History neurological disorder seizure , exception single febrile seizure childhood . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality Acute disease time enrolment Oral temperature &gt; = 37.5째C ( 99.5째F ) / axillary temperature &gt; = 37.5째C ( 99.5째F ) time enrolment . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first vaccine dose . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period .</criteria>
	<gender>Female</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Herpes Simplex vaccine</keyword>
	<keyword>Safety</keyword>
	<keyword>Adolescents</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>